News
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
Fintel on MSN1d
BMO Capital Downgrades Novo Nordisk A (NVO)Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback